May 13, 2026 06:42AM Immunic Inc. (IMUX) Misses Q1 EPS by 100c

Apr 30, 2026 06:53AM Immunic Inc. (IMUX) PT Raised to $22 at H.C. Wainwright

Apr 16, 2026 04:14PM Stifel Starts Immunic Inc. (IMUX) at Buy

Apr 15, 2026 07:28AM D. Boral Capital Downgrades Immunic Inc. (IMUX) to Hold

Apr 2, 2026 04:34PM Immunic Inc. (IMUX) files for 458.15M share offering by selling stockholders

Mar 31, 2026 06:30AM Immunic appoints Jon Congleton to board of directors

Mar 24, 2026 04:31AM Guggenheim Starts Immunic Inc. (IMUX) at Buy

Mar 10, 2026 06:30AM Immunic receives European patent for vidofludimus calcium dosing regimens

Mar 2, 2026 06:57AM Immunic Inc. (IMUX) PT Lowered to $5 at H.C. Wainwright

Feb 26, 2026 06:33AM Immunic Inc. (IMUX) Misses Q4 EPS by 53c

Nov 13, 2025 06:34AM Immunic Inc. (IMUX) Tops Q3 EPS by 2c

Nov 7, 2025 03:07AM Roth/MKM Starts Immunic Inc. (IMUX) at Buy

Oct 16, 2025 06:40AM Ladenburg Thalmann Assumes Immunic Inc. (IMUX) at Buy

Sep 29, 2025 05:58AM Chardan Capital Markets Starts Immunic Inc. (IMUX) at Buy, PT $3

Sep 25, 2025 06:31AM Immunic presents multiple sclerosis drug data at ECTRIMS congress

Sep 2, 2025 07:47AM Immunic Inc. (IMUX) PT Lowered to $4 at B.Riley

Aug 12, 2025 06:27AM H.C. Wainwright Reiterates Buy Rating on Immunic Inc. (IMUX)

Aug 7, 2025 06:33AM Immunic Inc. (IMUX) Misses Q2 EPS by 3c

Jun 24, 2025 06:31AM Immunic Inc. (IMUX) Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial

May 29, 2025 07:06AM Immunic (IMUX) Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025 04:04PM Immunic Inc. (IMUX) proposes public offering

Apr 30, 2025 07:31AM Immunic Inc. (IMUX) Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 9, 2025 08:11AM Immunic Inc. (IMUX) Prices 5.67M Share Offering at $0.90/sh

Mar 25, 2025 06:51AM William Blair Starts Immunic Inc. (IMUX) at Outperform

Feb 26, 2025 06:35AM Immunic Inc. (IMUX) Presents Key Vidofludimus Calcium Data

Feb 21, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Immunic Inc. (IMUX)

Feb 20, 2025 07:30AM Immunic's (IMUX) Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Nov 25, 2024 06:05AM H.C. Wainwright Starts Immunic Inc. (IMUX) at Buy

Nov 13, 2024 06:30AM Immunic Inc. (IMUX) Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856

Nov 7, 2024 06:33AM Immunic Inc. (IMUX) Misses Q3 EPS by 2c

Oct 22, 2024 06:30AM Immunic (IMUX) Reports Positive Outcome of Interim Analysis of Phase 3 ENSURE Program

Sep 18, 2024 06:30AM Immunic Inc. (IMUX) Presents Key Vidofludimus Calcium Data

Sep 16, 2024 07:43AM Piper Sandler Reiterates Overweight Rating on Immunic Inc. (IMUX)

Sep 16, 2024 07:04AM EF Hutton Starts Immunic Inc. (IMUX) at Buy

Sep 9, 2024 12:05PM Leerink Partners Assumes Immunic Inc. (IMUX) at Outperform, ' one of our top picks'

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Sep 4, 2024 07:41AM Piper Sandler Reiterates Overweight Rating on Immunic Inc. (IMUX)

Sep 4, 2024 07:14AM Immunic Inc. (IMUX) Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 27, 2024 12:31AM B.Riley Starts Immunic Inc. (IMUX) at Buy

Aug 8, 2024 06:33AM Immunic Inc. (IMUX) Tops Q2 EPS by 2c

Jul 24, 2024 06:30AM Immunic Inc. (IMUX) Appoints Simona Skerjanec to its Board

Jul 9, 2024 06:30AM Immunic Inc. (IMUX) Appoints Jason Tardio as COO and President